Journalists meet to discuss different aspects of biotechnology and its impact on society

NewsGuard 100/100 Score

More than 90 journalists from all over the world meet in Heidelberg, today, for the 4th Alumni Conference of the International Journalists’ Programmes (IJP). In keynote-speeches, panel discussions and excursions participants will discover different aspects of biotechnology and its impact on society. The conference is hosted by the Biotechnology Cluster Rhine-Neckar (BioRN) – one of the leading life science clusters in Europe.

From academia, economy and politics, renowned representatives such as nobel laureate Prof. Dr. Werner Arber have confirmed to participate. Topics include the future perspective of stem cell research, the global challenge of HIV and AIDS, effects of the financial crisis on biotech innovation, the emergence of world-class biotech clusters in Europe, as well as personalized medicine as a major driver of change in the world’s health economy.

“We are very pleased about the increasing interest of journalists in biotechnology and we appreciate the opportunity to provide new insights into this important future technology”, said Dr. Christian Tidona, Managing Director of the BioRN Cluster Management GmbH. ”Biotechnology affects a broad range of topics. By discussing economic, ethic and scientific aspects of biotechnology, IJP is proud to contribute to a better coverage”, emphasized Vassilios Theodossiou, Director IJP.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval